Praziquantel

Animal studies have found no embryotoxic or teratogenic effects.

A large number of women treated without damaging effects has been reported in the literature.

In accordance with WHO publication on praziquantel risk-benefit analysis, it has been shown that the benefits of treating fertile and pregnant women are much greater than the risks to their health and the health of their babies, where schistosomiasis and soil helminthiasis are endemically transmitted. The benefit of praziquantel treatment in pregnant women consists of less anemia in the mothers and improvement of birth weight and survival of the baby. Consequently, praziquantel can be used during pregnancy, as clinically necessary.

Praziquantel is excreted 0.0008% in milk.

It is not known if can cause a pharmacological effect in infants.

For a short duration treatment, breast-feeding should be discontinued during treatment and for the subsequent 24 hours.

Fertility

There are no clinical data on fertility.

Praziquantel has shown no effect on fertility in animal studies.

Praziquantel has moderate influence on the ability to drive and use machines. Patients should be aware that side effects such as dizziness, lightheadedness, or drowsiness may occur after taking praziquantel. Therefore it is recommended to avoid driving or operating machinery during the treatment period and for 24 hours after treatment discontinuation.